RM
RMTI.US Rockwell Medical Inc
- Market cap
- USD 26.3M
- P/E
- -
- P/B
- 0.84x
- ROE
- -20.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RMTI.US undervalued?
Graham numberThe Graham number of Rockwell Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rockwell Medical Inc fundamental analysis
No fundamental analysis for Rockwell Medical Inc yet.
Rockwell Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rockwell Medical Inc
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid …
Full company profileRockwell Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rockwell Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 53.3M | 57.3M | 63.4M | 61.3M | 62.2M | 61.9M | 72.8M | 83.6M | 101M | 69.3M | 72.3M |
| Gross Profit | 6.75M | 3.70M | -1.58M | 2.84M | 2.73M | -2.42M | 4.08M | 8.70M | 17.5M | 11.7M | 12.3M |
| Operating Income | -20.2M | -25.9M | -32.4M | -34.1M | -28.4M | -30.3M | -16.8M | -6.67M | 608K | -4.69M | -6.35M |
| EBITDA | -18.6M | -25.4M | -31.5M | -31.5M | -26.7M | -27.8M | -16.2M | -4.69M | 2.95M | -2.00M | -3.60M |
| Net Income | -19.8M | -25.9M | -32.1M | -34.1M | -30.9M | -32.7M | -18.7M | -8.44M | -480K | -5.31M | -6.80M |
| EPS | -43 | -56 | -67 | -62 | -45 | -38 | -19 | -3.62 | -0.15 | -1.48 | -1.71 |
| Balance Sheet | |||||||||||
| Total Assets | 83.2M | 58.8M | 52.6M | 44.3M | 77.7M | 48.6M | 46.6M | 52.2M | 59.2M | 57.1M | 57.1M |
| Total Liabilities | 30.2M | 25.9M | 25.3M | 24.0M | 43.6M | 46.0M | 32.5M | 30.9M | 26.6M | 20.2M | 23.9M |
| Shareholders' Equity | 53.0M | 32.9M | 27.3M | 20.3M | 34.2M | 2.54M | 14.1M | 21.3M | 32.6M | 37.0M | 33.1M |
| Cash & Short-term Investments | 57.9M | 33.1M | 33.5M | 26.0M | 58.7M | 22.4M | 21.5M | 10.9M | 21.6M | 25.0M | 22.5M |
| Total Debt | - | - | - | 4.04M | 23.9M | 28.9M | 16.4M | 13.4M | 13.5M | 12.5M | 13.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.5M | -21.1M | -20.4M | -27.3M | -29.6M | -33.5M | -16.9M | -9.41M | 4.20M | -659K | 516K |
| Capital Expenditure | 355K | 1.68M | 994K | 1.34M | 1.05M | 522K | 281K | 284K | 1.01M | 542K | 2.78M |
| Free Cash Flow | -12.8M | -22.8M | -21.4M | -28.6M | -30.7M | -34.1M | -17.2M | -9.70M | 3.19M | -1.20M | 516K |
| Ratios | |||||||||||
| ROE | -37.4% | -78.8% | -117.8% | -168.0% | -90.4% | -1,288.9% | -132.4% | -39.6% | -1.5% | -14.4% | -20.5% |
| ROA | -23.8% | -44.1% | -61.1% | -77.0% | -39.7% | -67.3% | -40.1% | -16.2% | -0.8% | -9.3% | -11.9% |
| Net Profit Margin | -37.2% | -45.2% | -50.7% | -55.7% | -49.7% | -52.8% | -25.7% | -10.1% | -0.5% | -7.7% | -9.4% |
| Debt to Equity | - | - | - | 0.20x | 0.70x | 11.40x | 1.16x | 0.63x | 0.42x | 0.34x | 0.41x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rockwell Medical Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 6.00K | 0.01 | - |
| 2020 | USD 22.5M | 33 | - |
| 2019 | USD 148K | 0.27 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jul 1, 2026.
Who owns Rockwell Medical Inc
- Insiders 15.00%
- Institutions 7.19%
- Public & others 77.82%
- Shares outstanding 3.97M
- Free float 3.51M
Top funds holding RMTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 84.5K | 2.13% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 19.6K | 0.49% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 5.23K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 4.95K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.07K | 0.05% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.06K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding RMTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.23M | 3.10% | +4.02% | Jun 2026 |
| Geode Capital Management, LLC | 364K | 0.92% | -15.17% | Jun 2026 |
| Jane Street Group LLC | 245K | 0.62% | +210.59% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 233K | 0.59% | +0.61% | Jun 2026 |
| Sontag Advisory LLC | 152K | 0.38% | 0.00% | Jun 2026 |
| BlackRock Inc | 145K | 0.36% | -38.84% | Jun 2026 |
| State Street Corp | 101K | 0.25% | 0.00% | Jun 2026 |
| Northern Trust Corp | 91.9K | 0.23% | -12.11% | Jun 2026 |
| UBS Group AG | 70.0K | 0.18% | -60.86% | Jun 2026 |
| GSA Capital Partners LLP | 69.8K | 0.18% | 0.00% | Jun 2026 |
| Corsair Capital Management LLC | 50.0K | 0.13% | 0.00% | Jun 2026 |
| LPL Financial Corp | 40.3K | 0.10% | -1.19% | Jun 2026 |
| Renaissance Technologies Corp | 35.9K | 0.90% | -0.29% | Sep 2026 |
| WEALTHTRUST AXIOM LLC | 33.0K | 0.08% | -15.60% | Jun 2026 |
| Richmond Brothers Inc | 30.6K | 0.08% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 24.7K | 0.06% | 0.00% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 21.9K | 0.06% | -35.07% | Jun 2026 |
| Tower Research Capital LLC | 14.4K | 0.04% | +604.51% | Jun 2026 |
| Burford Brothers Inc | 14.2K | 0.04% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 11.2K | 0.03% | -76.12% | Jun 2026 |
Rockwell Medical Inc company profile
- Company name
- Rockwell Medical Inc
- Ticker
- RMTI.US
- Exchange
- USA Stocks
- Listed since
- Jan 27, 1998
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 157
- Fiscal year end
- December
- Address
- 30142 South Wixom road, Wixom, MI, United States, 48393
- Phone
- 248 960 9009
- Website
- rockwellmed.com
About Rockwell Medical Inc
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Rockwell Medical Inc management
6- Dr. Mark Strobeck Ph.D.President, CEO & Director · born 1971
- Mr. Jesse NeriSenior VP & CFO · born 1978
- Ms. Megan C. TimminsExecutive VP, Chief Legal Officer & Secretary · born 1973
- Ms. Heather H. HunterSenior VP & COO · born 1979
- Mr. Nicholas FanslauController & Principal Accounting Officer · born 1985
- Mr. Timothy T. CholeSenior VP & Chief Commercial Officer · born 1974